New drug SCTB14 takes on standard immunotherapy in lung cancer showdown
NCT ID NCT07362459
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new experimental drug, SCTB14, to the standard immunotherapy pembrolizumab (Keytruda) as a first treatment for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels (TPS ≥10%). About 246 participants will receive either SCTB14 or pembrolizumab every 3 weeks. The main goal is to see if SCTB14 can delay cancer growth better than the current standard.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCTB14 (an experimental immunotherapy drug given by IV every 3 weeks)
What this could lead to
If SCTB14 works better than pembrolizumab, it could offer a new first-line immunotherapy option for people with advanced lung cancer.
What could go wrong
This is an early-stage comparison; SCTB14 may not prove superior or could have unexpected side effects. The trial is still recruiting, so results are years away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••